Royalty Pharma PLC (RPRX)
27.40
-0.06
(-0.22%)
USD |
NASDAQ |
Jun 10, 16:00
27.40
0.00 (0.00%)
After-Hours: 20:00
Royalty Pharma Cash from Operations (Quarterly): 664.64M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 664.64M |
| December 31, 2023 | 772.63M |
| September 30, 2023 | 573.52M |
| June 30, 2023 | 607.82M |
| March 31, 2023 | 1.034B |
| December 31, 2022 | 569.93M |
| September 30, 2022 | 538.83M |
| June 30, 2022 | 574.95M |
| March 31, 2022 | 460.27M |
| December 31, 2021 | 489.96M |
| September 30, 2021 | 469.76M |
| Date | Value |
|---|---|
| June 30, 2021 | 531.72M |
| March 31, 2021 | 526.10M |
| December 31, 2020 | 565.67M |
| September 30, 2020 | 508.85M |
| June 30, 2020 | 489.00M |
| March 31, 2020 | 471.10M |
| December 31, 2019 | 1.667B |
| September 30, 2019 | -769.78M |
| June 30, 2019 | 336.79M |
| March 31, 2019 | 432.98M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-769.78M
Minimum
Sep 2019
1.667B
Maximum
Dec 2019
554.14M
Average
535.27M
Median
Cash from Operations (Quarterly) Benchmarks
| Cytokinetics Inc | -129.51M |
| Agios Pharmaceuticals Inc | -99.87M |
| Viatris Inc | 614.60M |
| Arrowhead Pharmaceuticals Inc | -92.38M |
| Insmed Inc | -184.04M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -86.65M |
| Cash from Financing (Quarterly) | -212.00M |
| Free Cash Flow | 2.619B |
| Free Cash Flow Per Share (Quarterly) | 1.112 |
| Free Cash Flow to Equity (Quarterly) | 660.55M |
| Free Cash Flow to Firm (Quarterly) | 701.45M |
| Free Cash Flow Yield | 15.92% |